Neha Vora

•   Master of Science in Nursing (MSN), APRN
  Vanderbilt University, Nashville, Tennessee (2025)
• Bachelor of Science in Nursing (BSN), RN
  Bellarmine University, Louisville, Kentucky (2023)
• Western Kentucky University, Bowling Green, Kentucky (2018)
• Bachelor of Science in Biology
  Kentucky Wesleyan College, Owensboro, Kentucky (2015)

• Director, Study Coordinator
  Research Integrity – Owensboro, Kentucky (2025 – Present)
• Study Coordinator
  Research Integrity – Owensboro, Kentucky (2016 – 2022)
  Conduct clinical research studies to document the efficacy and safety of adult and pediatric health care products including devices. Maintain contact with a large number of sponsors and CROs as required for coordinating.

Clinical Support Roles

• One Health McAuley Primary Care – Owensboro, Kentucky (2012 / 2015)
• Owensboro Health Women’s Center – Owensboro, Kentucky (2015)
• Bidada Medical, Surgical, and Dental Camp – Gujarat, India (2015)
• Mission Trip – Honduras, Central America (2010)

•  ACLS: current certificate holder 
• GCP CITI: current certificate holder
• IATA: computer training; current certificate holder
• CPR: BLS certificate
• EDC Experience: sponsor training; includes Medidata Rave, DataLabs, InForm, Oracle, and Perspective MyTrials (6 yrs)
• Questionnaires: sponsor/national training; includes PAC-QOL, PAC-SYM, Disease Severity, Disease QOL, Global Symptom Relief, Global Pain Relief, MIDAS, PHQ-9, HIS-Q, IPSS
• EKG Acquisitions: site training per cardiologist; lead placement per sponsor recommendations; conducting for 6 yrs
• Electronic Diaries: sponsor- and vendor-provided training
• EKG Transmission: per sponsor & vendor training; both computer/phone line (6 yrs)
• CSSR-S: Sponsor & national training; certificate may be available (6 yrs)
• Vitals: include temp, wt, ht, BP, HR; site training; manual/automatic BP; oral, temporal, auricle temp (6 yrs)
• IXRS: sponsor training; Bracket, Perspective MyTrials (6 yrs)
• Centrifuge training: by site including cup size, RPMs, and calibrations (6 yrs)
• Lab Sample Processing: sponsor, central lab specific, local lab & site training (6 yrs)
• ERT Site Pad: training per sponsor/vendor (6 yrs)
• Rapid Result Labs: include drug screening, nicotine, pregnancy, urine dip stick (6 yrs)
• Consenting Patients
• Inclusion/Exclusion review
• Patient Recruitment
• Patient Retention
• Obtain Medical Records for PI review
• Maintain study supplies
• Watch over Rights and Welfare of the Patients
• PK Ice Baths: preparing samples
• PHT experience
• Transmission of ultrasound, x-ray, CT scan, nuclear medicine, echo, and DXA via DICOM
• Assist in audits (sponsor and/or FDA)
• Attends Investigator Meetings
• Monitor/Maintain temperature logs
• Maintain Drug Logs
• Dispense IP
• Assist the PI in delegated duties
• Administering questionnaires per protocol
• Entering data into eCRF
• Resolving queries
• Protocol adherence
• Creating and completing source documentation
• Drawing and processing of labs
• Infusion pump settings
• Blinded/Unblinded Pharmacist experience

• BI 456906 – Cardiovascular safety study in overweight or obese patients with comorbidities
• LIBREXIA-AF – Milvexian vs Apixaban in Atrial Fibrillation
• TA-8995-304 Prevail – Obicetrapib in ASCVD
• BP-24-001 – COVID-19 vaccination immunologic correlates study
• VICTORION-1 PREVENT – Inclisiran for primary prevention of cardiovascular events
• KARDIA-3 – Zilebesiran in patients with hypertension
• ADG20 EVADE – COVID-19 prevention with ADG20
• AZALEA – Abelacimab vs Rivaroxaban in AF
• AZD3427 – Safety and pharmacokinetics in heart failure patients
• SEL-212 – Gout treatment study
• PURSUIT – Viveve RF SUI trial
• CLN-301 – Tolperisone for back muscle spasm
• ZOLL HF – µCor treatment in heart failure
• RM08-3009 – Nitazoxanide for common cold
• RM08-3008 – Nitazoxanide for mild/moderate COVID-19
• MATISSE – RSV vaccine in infants (Pfizer)
• CATCH-HF – Heart failure biomarker characterization
• PAT-CR-302 – Patiromer for hyperkalemia
• Orion 4 – Inclisiran cardiovascular outcome study
• ORESA – T89 angina treatment
• SAGE-217 (SAGE 301) – Severe postpartum depression treatment
• Brexanolone (SAGE 304) – Adolescent PPD safety study
• VITALITY – Vericiguat in HF with preserved EF
• Evaluate HF – Sacubitril/valsartan vs enalapril for central aortic stiffness
• TRAVERSE – Testosterone therapy cardiovascular impact
• AMPLITUDE – Efpeglenatide cardiovascular outcomes in Type 2 Diabetes
• PROVE-HF – Sacubitril/valsartan biomarker study
• ZOLL 90D0109 – Heart Failure Optimization Study
• R-Pharm CREDO 3 – Olokizumab in RA, TNF-alpha resistant
• R-Pharm CREDO 2 – Olokizumab in RA, methotrexate resistant
• R-Pharm CREDO 4 – Open-label Olokizumab safety study
• COL-MIG 305 (Gladiator) – Lasmiditan migraine safety study
• COL-MIG 302 (Spartan) – Lasmiditan migraine dose study
• BL 400-303 – Chronic use of BLI400 laxative in adults